Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells

Background: Triple-negative breast Cancer (TNBC) exhibits biologically aggressive behavior and has a poor prognosis. Novel molecular targeting agents are needed to control TNBC. Recent studies revealed that the non-canonical Hedgehog (Hh) signaling pathway plays important roles in the regulation of Cancer Stem Cells (CSCs) in breast Cancer. Therefore, the anti-cell growth and anti-CSC effects of the non-canonical Hh inhibitor GANT61 were investigated in TNBC cells.

Methods: The effects of GANT61 on cell growth, cell cycle progression, Apoptosis, and the proportion of CSCs were investigated in three TNBC cell lines. Four ER-positive breast Cancer cell lines were also used for comparisons. The expression levels of effector molecules in the Hh pathway: glioma-associated oncogene (Gli) 1 and GLI2, were measured. The combined effects of GANT61 and paclitaxel on anti-cell growth and anti-CSC activities were also investigated.

Results: Basal expression levels of GLI1 and GLI2 were significantly higher in TNBC cells than in ER-positive breast Cancer cells. GANT61 dose-dependently decreased cell growth in association with G1-S cell cycle retardation and increased Apoptosis. GANT61 significantly decreased the CSC proportion in all TNBC cell lines. Paclitaxel decreased cell growth, but not the CSC proportion. Combined treatments of GANT61 and paclitaxel more than additively enhanced anti-cell growth and/or anti-CSC activities.

Conclusions: The non-canonical Hh inhibitor GANT61 decreased not only cell growth, but also the CSC population in TNBC cells. GANT61 enhanced the anti-cell growth activity of paclitaxel in these cells. These results suggest for the first time that GANT61 has potential as a therapeutic agent in the treatment of patients with TNBC.